Evaluation of the mechanism of inactivation of plasminogen activator inhibitor-1 by monoclonal antibodies using a stable variant

Fibrinolysis and Proteolysis

Volumn 12, Issue 5, 1998, Pages 277-282

  Vleugels, N ^a   Gils, A ^a   Mannaerts, S ^a   Knockaert, I ^a   Declerck, P J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ANTIGEN BINDING; ARTICLE; ENZYME INACTIVATION; HALF LIFE TIME; PRIORITY JOURNAL; PROTEIN STABILITY;

EID: 0031791204     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(98)80020-9     Document Type: Article

References (34)

1. Kruithof EK, Tran Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913.
2. Pannekoek H, Veerman H, Lambers H, et al. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J 1986; 5: 2539-2544.
3. Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776-6780.
4. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269: 15957-15960.
5. Schechter I, Berger A. On the size of the active site in proteases. Biochem Biophys Res Commun 1967; 27: 157-162.
6. Laskowski M Jr, Kato I. Protein inhibitors of proteinases. Annu Rev Biochem 1980; 49: 593-626.
7. Huber R, Carrell RW. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry 1989; 28: 8951-8966.
8. Carrell RW, Boswell DR, Barrett, Salvesen. In: (eds) Serpins: the superfamily of plasma serine proteinase inhibitors. Proteinase Inhibitors. London: Elsevier 1986: 403-420.
9. Wright HT, Scarsdale JN. Structural basis for serpin inhibitor activity. Proteins 1995; 22: 210-225.
10. Declerck PJ, De Mol M, Vaughan DE, Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a non-inhibitory substrate for tissue-type plasminogen activator. J Biol Chem 1992; 267: 11693-11696.
11. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-11587.
12. Masuda T, Yasue H, Ogawa H. Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina. Am Heart J 1992; 124: 314-319.
13. Aznar J, Estelles A, Tormo G et al. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988; 59: 535-541.
14. Musumi I, Ogawa H, Masuda T, Sakamoto T, Okumura K, Yasue H. Increased plasma plasminogen activator inhibitor activity after coronary spasm. Int J Cardiol 1993; 41: 21-29.
15. Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453-1456.
16. Robbie LA, Booth NA, Brown PAJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterio Thromb Vasc Biol 1996; 16: 539-45.
17. Sawa H, Sobel BE, Fujii S. Inhibition of type-1 plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscle cells. J Biol Chem 1994; 269: 14149-14152.
18. Charlton PA, Faint RW, Bent F et al. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor 1 activity. Thromb Haemost 1996; 75: 808-815.
19. Abrahamson T, Björquist P, Deinum J et al. An antibody fragment against PAI-1 inhibits PAI-1 activity and stimulates fibrinolysis in vitro and in vivo. Fibrinolysis 1994; 8: 55-56.
20. van Giezen JJ, Wahlund G, Nerme, Abrahamsson T. The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis. Thromb Haemost 1997; 77: 964-969.
21. Levi M, Biemond BJ, van Zonneveld AJ, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-312.
22. Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation 1995; 91: 1175-1181.
23. Ngo TH, Debrock S, Declerck P. Identification of functional synergism between monoclonal antibodies. Application to the enhancement of plasminogen activator inhibitor-1 neutralizing effects. FEBS Lett 1997; 416: 373-376.
24. Charlton P, Faint R, Barnes C et al. Xr5118, a novel modulator of plasminogen activator inhibitor 1 (PAI-1), increases endogenous tPA activity in the rat. Fibrinolysis & Proteolysis 1997; 11: 51-56.
25. Eitzman DT, Fay WP, Lawrence DA et al. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 1995; 95: 2416-2420.
26. Debrock S, Declerck PJ. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochim Biophys Acta 1997; 1337: 257-266.
27. Berkenpas MB, Lawrence DA, Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 1995; 14: 2969-2977.
28. Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgGl, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry 1978; 15: 429-436.
29. Audenaert AM, Knockaert I, Collen D, Declerck PJ. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop. J Biol Chem 1994; 269: 19559-19564.
30. Gils A, Knockaert I, Declerck PJ. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Biochemistry 1996; 35: 7474-7481.
31. Verheijen JH, Chang GT, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 1984; 51: 392-395.
32. Jönsson U, Malmqvist M. Real time biospecific interaction analysis. The integration of surface plasmon resonance detection, general biospecific interface chemistry and microfluidics into one analytical system. In: (eds). Advances in Biosensors. JAI Press, 1992: 291-336.
33. Debrock S, Declerck PJ. Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop. Thromb Haemost 1998; 79: 597-601.
34. Bjorquist P, Ehnebom J, Inghardt T, Deinum J. Epitopes on plasminogen activator inhibitor type 1 important for binding to tissue plasminogen activator. Biochim Biophys Acta 1997; 1341: 87-98.